Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

Journal of virology - 1 Jun 2012

Tsibris Athe M N, Hu Zixin, Paredes Roger, Leopold Kay E, Putcharoen Opass, Schure Allison L, Mazur Natalie, Coakley Eoin, Su Zhaohui, Gulick Roy M, Kuritzkes Daniel R

Abstract excerpt

We previously described an HIV-1-infected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, during 28 weeks of therapy (Tsibris AM et al., J. Virol. 82:8210-8214, 2008). To investigate the decay of VCV resistance mutations, a standard clonal analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Enfuvirtide
Share to HIV Envelope Protein gp120

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to Peptide Fragments

Share to Piperazines

Share to Pyrimidines

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 22491471
DOI: 10.1128/JVI.00286-12
PMCID: PMC3393533

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22491471-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.PMID 22491471Read ↗

Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Semantic proximity Read ↗

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.Semantic proximity Read ↗

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected SubjectSemantic proximity Read ↗

Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.Semantic proximity Read ↗

Characterization of Emergent HIV Resistance in Treatment‐Naive Subjects Enrolled in a Vicriviroc Phase 2 TrialSemantic proximity Read ↗

Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.Semantic proximity Read ↗

Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic.Semantic proximity Read ↗

Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist VicrivirocSemantic proximity Read ↗

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.Semantic proximity Read ↗

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).Semantic proximity Read ↗

Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of DrugSemantic proximity Read ↗

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.